NASH Network launches real-world evidence pilot study

The NASH Network, in collaboration with the Kinetix Group and partnered with Echosens, launched a real-world evidence study to optimize care delivery for patients with nonalcoholic steatohepatitis, according to a press release.

“Nonalcoholic fatty liver disease is an asymptomatic disease, affecting one in three Americans,” Douglas Dieterich, MD, from the Mt. Sinai School of Medicine in New York, said in a press release. “While a majority of patients with NAFLD will not advance to liver fibrosis or cirrhosis, it is critical to develop effective and efficient models to identify the subset of NAFLD patients with NASH in the settings where they receive care.”

The NASH Network (NASHNet) pilot was designed to evaluate an interdisciplinary model across hepatology, endocrinology, primary care and other specialist health systems to support early risk stratification and improve cost-effective NAFLD management.

According to the release, NASHNet developed the study in response to the growing pipeline of potential NAFLD therapies and the recent projection that the global NASH market will reach $21.5 billion by 2025.

Reference: